# AstraZeneca Plc Lynparza significantly delayed disease progression

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-lynparza-significantly-delayed-disease-progression/412768025
- Published: 2019-02-26T07:54:43+00:00
- Author: Charlotte Edwards

**[AstraZeneca Plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))**
and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US
and Canada) today announced positive results from the Phase III POLO trial.

Results from the trial showed a statistically-significant and clinically-meaningful
improvement in progression-free survival (PFS) with Lynparza (olaparib) vs. placebo.
The safety and tolerability profile of Lynparza was consistent with previous trials.

POLO is a randomised, double-blinded, placebo-controlled trial exploring the efficacy
of Lynparza tablets as 1st-line maintenance monotherapy in patients with germline
BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas (pancreatic cancer)
whose disease has not progressed on platinum-based chemotherapy.

> **José Baselga, Executive Vice President, Research and Development, Oncology,
> said:** “This is the first positive Phase III trial of any PARP inhibitor in germline
> BRCA-mutated metastatic pancreatic cancer, a devastating disease with critical
> unmet need. The results of POLO provide further evidence of the clinical benefit
> of Lynparza across a variety of BRCA-mutated tumour types. We will discuss these
> results with global health authorities as soon as possible.”
> **Roy Baynes, Senior Vice President and Head of Global Clinical Development, Chief
> Medical Officer, MSD Research Laboratories, said:** “Trials like POLO demonstrate
> the shared commitment of MSD and AstraZeneca to assess treatments for difficult-
> to-treat cancers. The clinically-meaningful results of this trial potentially 
> support the value of testing for germline BRCA mutations in patients with metastatic
> pancreatic cancer.”

AstraZeneca and MSD plan to present the full data from the trial at a forthcoming
medical meeting.

**About POLO**

POLO is a Phase III randomised, double-blinded, placebo-controlled, multicentre 
trial of Lynparza tablets (300mg twice daily) as maintenance monotherapy vs. placebo.
The trial randomised 154 patients with gBRCAm metastatic pancreatic cancer whose
disease had not progressed on 1st-line platinum-based chemotherapy. Patients were
randomised (3:2) to receive Lynparza or placebo until disease progression. The primary
endpoint was PFS and key secondary endpoints included overall survival, time to 
second disease progression, overall response rate, disease control rate and health-
related quality of life.

**About Lynparza**

Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment
to block DNA damage response in cells/tumours harbouring a deficiency in homologous
recombination repair (HRR), such as mutations in BRCA1 and/or BRCA2. Inhibition 
of PARP with Lynparza leads to the trapping of PARP bound to DNA single-strand breaks,
stalling of replication forks, their collapse and the generation of DNA double-strand
breaks and cancer cell death. Lynparza is being tested in a range of PARP-dependent
tumour types with defects and dependencies in the DDR.

Lynparza, which is being jointly developed and commercialised by AstraZeneca and
MSD, is approved for multiple indications in advanced ovarian cancer and metastatic
breast cancer and has been used in over 20,000 patients worldwide. Lynparza has 
the broadest and most advanced clinical trial development programme of any PARP 
inhibitor, and AstraZeneca and MSD are working together to understand how it may
affect multiple PARP-dependent tumours as a monotherapy and in combination across
multiple cancer types. Lynparza is the foundation of AstraZeneca’s industry-leading
portfolio of potential new medicines targeting DDR mechanisms in cancer cells.

**About pancreatic cancer**

Pancreatic cancer is the 12th most common cancer worldwide,1 with 466,000 new cases
in 2018 alone.1 Germline BRCA-mutated pancreatic cancer accounts for five to seven
percent of all cases globally.2 With the worst survival rate of the most common 
cancers,3 it is the 4th leading cause of cancer death,4 and less than seven percent
of patients survive more than five years after diagnosis.3 Early diagnosis of pancreatic
cancer is difficult, as often there are no symptoms until it is too late.5 Around
80% of patients are diagnosed at the metastatic stage.6

**About BRCA mutations**

BRCA1 and BRCA2 are human genes that produce proteins responsible for repairing 
damaged DNA and play an important role in maintaining the genetic stability of cells.
When either of these genes is mutated, or altered, such that its protein product
either is not made or does not function correctly, DNA damage may not be repaired
properly, and cells become unstable. As a result, cells are more likely to develop
additional genetic alterations that can lead to cancer.

**About the AstraZeneca and MSD strategic oncology collaboration**

In July 2017, AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US, known as MSD
outside the United States and Canada, announced a global strategic oncology collaboration
to co-develop and co-commercialise Lynparza, the world’s first PARP inhibitor, and
potential new medicine selumetinib, a MEK inhibitor, for multiple cancer types. 
Working together, the companies will develop Lynparza and selumetinib in combination
with other potential new medicines and as monotherapies. Independently, the companies
will develop Lynparza and selumetinib in combination with their respective PD-L1
and PD-1 medicines.

**About AstraZeneca in Oncology**

AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly-growing 
portfolio of new medicines that has the potential to transform patients’ lives and
the Company’s future. With at least six new medicines to be launched between 2014
and 2020, and a broad pipeline of small molecules and biologics in development, 
we are committed to advance Oncology as a key growth driver for AstraZeneca focused
on lung, ovarian, breast and blood cancers. In addition to our core capabilities,
we actively pursue innovative partnerships and investments that accelerate the delivery
of our strategy, as illustrated by our investment in Acerta Pharma in haematology.

By harnessing the power of four scientific platforms – Immuno-Oncology, Tumour Drivers
and Resistance, DNA Damage Response and Antibody Drug Conjugates – and by championing
the development of personalised combinations, AstraZeneca has the vision to redefine
cancer treatment and one day eliminate cancer as a cause of death.

**About AstraZeneca**

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the
discovery, development and commercialisation of prescription medicines, primarily
for the treatment of diseases in three therapy areas – Oncology, Cardiovascular,
Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and
its innovative medicines are used by millions of patients worldwide.

Share on:
